Galeterone companion diagnostic

Drug Profile

Galeterone companion diagnostic

Alternative Names: AR-V7 companion diagnostic

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tokai Pharmaceuticals
  • Developer Novus Therapeutics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 31 Mar 2017 QIAGEN in-licenses AR-V7 biomarker from Johns Hopkins University
  • 24 Jun 2015 Phase-III clinical trials in Prostate cancer (Diagnosis) in USA (unspecified route)
  • 15 Jan 2015 Galeterone companion diagnostic is available for licensing as of 15 Jan 2015. http://www.tokaipharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top